Healx

Our track record and expertise

Great vision needs a strong team to drive it forward. Our team consists of experts in drug development, drug repurposing and computational biology.

Meet the Healx Senior Team

Dr Tim Guilliams

Dr Tim Guilliams

Chief Executive Officer

Tim is a social entrepreneur passionate about delivering the next generation of therapeutics to rare disease patients in need. He is the Founder and Chief Executive of Healx and the Co-Founder and Chair of the Cambridge Rare Disease Network (CRDN), a charity aiming to foster dialogue and awareness around rare diseases in Cambridge, UK.

Prior to Healx and CRDN, Tim worked on University-Industry interactions and cluster dynamics in the area of Life Sciences for the UK Government Department for Business, Innovation and Skills (BIS). He obtained his PhD in the field of Biophysical Neuroscience at the University of Cambridge, where his research related to the development of antibody fragments as novel biophysical and therapeutic tools for Parkinson’s disease. As a PhD student, Tim co-founded multiple successful student societies, including the Cambridge University Science and Policy Exchange (CUSPE), and was involved with Innovation Forum, Oxbridge Biotech Roundtable (OBR) and the Cambridge University Technology and Enterprise Club (CUTEC). He is also a Junior Associate Fellow of the Centre for Science and Policy (CSaP). Before moving to Cambridge, he obtained an MEng & BEng in Bio-Engineering from the University of Brussels (VUB).

Bio
Dr David Cavalla

Dr David Cavalla

Chief Scientific Officer

David Cavalla has 30 years experience in various senior scientific and commercial roles within the pharmaceutical industry, and 15 years in drug repurposing; previously he was founder and CEO of Arachnova Ltd, and prior to that, at Glaxo Group Research Ltd and Napp Research Centre. He is also founder and principal of Numedicus Limited.

He is author of Off-Label Prescribing: Justifying Unapproved Medicine, and one of the first advocates of drug repurposing, using this strategy to create three first-in-class developmental products to have successfully passed human proof of concept clinical stages. He obtained a first degree and PhD at Cambridge University and spent two years as a visiting Fellow at the NIMH, Washington, DC. He is author/inventor of over 70 published papers and patents.

Bio
Dr Andreas Bender

Dr Andreas Bender

Chief Technology Officer

Andreas Bender is a Lecturer for Molecular Informatics with the Centre for Molecular Informatics at the University of Cambridge. Until April 2010 he was an Assistant Professor for Cheminformatics and Pharmaceutical IT with the Leiden / Amsterdam Center for Drug Research and Head of the Pharma-IT Platform at Leiden University. In his work, he is involved with the analysis of various kinds of bioactivity data and the generation of property prediction models, mainly for small molecules.

Bio
Richard Smith

Richard Smith

Head of Software Engineering

Richard has over 15 years experience building databases and websites for biology research in both academia and industry. In the Genetics Department at Cambridge University he led development of InterMine, an open source biological data warehousing platform. InterMine went on to be used at several major academic sites and projects around the world.

Richard also founded Nowomics, a website to help life scientists track the latest papers relevant to their research by following genes, diseases and other keywords to create a personalised Twitter-like news feed.

Bio
Dr Ian Roberts

Dr Ian Roberts

Head of Bioinformatics

As senior investigator at the MRC Cancer Cell Unit, Cambridge, Ian lead the development of molecular cytogenetic and genomics approaches for the discovery of disease genes in small round blue cell tumours, and cervical carcinoma. During this time Ian developed algorithms for copy number imbalance analysis and integration with expression data using array based techniques.

Following a move to industry, as Head of Informatics at Population Genetics Technologies Ltd Ian lead the development of Next Generation DNA Sequencing (NGS) variant discovery pipelines. Ian continued to develop NGS based variant discovery workflows as Senior Bioinformatician at 14M Genomics, before joining Healx in 2016.

Bio
Michale Bouskila-Chubb

Michale Bouskila-Chubb

Head of Business Development

Prior to joining Healx in 2017, Michale held various commercial positions in management consultancy, sales, technology transfer and pharmaceutical business development. Michale has a strong background in all aspects of IP exploitation from University technologies as well as commercial strategy. After a research career in the field of physiology and human metabolism in both academia and industry, Michale completed an MBA specialising in Life Sciences from the Open University Business School. Michale also holds a Pharmacy doctorate and a Toxicology Master’s degree from Paris V University as well as a PhD from the University of Dundee.

Bio

Board of Directors

Dr David Brown

Dr David Brown

Chairman

Dr David Brown has 40 years experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. He served with 4 of the top 10 pharmaceutical companies: Zeneca, Pfizer, GlaxoWellcome, and Hoffman La-Roche. Whilst at Pfizer he was named co-inventor on the patent for Viagra, and for 8 years he led the team that invented and developed Viagra through to proof of clinical efficacy in male impotence. The drug is also marketed for treatment of pulmonary hypertension under the trade name Revatio. He also had a pivotal role in the discovery of Relpax, a treatment for migraine. Together these drugs have achieved sales of over $30 billion. While at Roche in Switzerland, he was a Director of the company and, as Global Head of Drug Discovery, he had responsibility for productivity of over 2000 scientists at Roche’s five research sites in the USA, Europe and Asia.

David subsequently co-founded antibody company Crescendo Biologics and serves on the boards of Healx Ltd (Chair), ProFactor Pharma Ltd (Chair) and Babraham Institute Enterprise Ltd (Chair). He is a Trustee (Director) of two charities, Antibiotic Research UK, dedicated to solving the looming problem of antibiotic resistance; and Friends of Manjushree Vidyapith School and Orphanage, a charity he co-founded in 2005 to help destitute orphans in South Tibet.

Bio
Dr Jonathan Milner

Dr Jonathan Milner

Dr Darrin Disley

Dr Darrin Disley

Advisers

Dr Elia Stupka

Dr Elia Stupka

Prof Steve Jackson

Prof Steve Jackson

Dr Bruce Bloom

Dr Bruce Bloom

Dr Ronjon Nag

Dr Ronjon Nag

Dr Nick Sireau

Dr Nick Sireau

Ms Hanadi Jabado

Ms Hanadi Jabado

Dr Martino Picardo

Dr Martino Picardo

Prof Alan Barrell

Prof Alan Barrell